200 related articles for article (PubMed ID: 2422109)
1. Keratin and epithelial membrane antigen immunoreactivity in nonneoplastic fibrous pleural lesions: implications for the diagnosis of desmoplastic mesothelioma.
Epstein JI; Budin RE
Hum Pathol; 1986 May; 17(5):514-9. PubMed ID: 2422109
[TBL] [Abstract][Full Text] [Related]
2. The separation of benign and malignant mesothelial proliferations.
Churg A; Colby TV; Cagle P; Corson J; Gibbs AR; Gilks B; Grimes M; Hammar S; Roggli V; Travis WD
Am J Surg Pathol; 2000 Sep; 24(9):1183-200. PubMed ID: 10976692
[TBL] [Abstract][Full Text] [Related]
3. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
4. Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.
Kawai T; Greenberg SD; Truong LD; Mattioli CA; Klima M; Titus JL
Am J Pathol; 1988 Feb; 130(2):401-10. PubMed ID: 2449084
[TBL] [Abstract][Full Text] [Related]
5. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
Sheibani K; Battifora H; Burke JS
Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
[TBL] [Abstract][Full Text] [Related]
6. CD-34 and keratin expression distinguishes solitary fibrous tumor (fibrous mesothelioma) of pleura from desmoplastic mesothelioma.
Flint A; Weiss SW
Hum Pathol; 1995 Apr; 26(4):428-31. PubMed ID: 7535740
[TBL] [Abstract][Full Text] [Related]
7. [Immunopathology of diffuse malignant mesothelioma].
Stosiek P; Goertchen R
Zentralbl Allg Pathol; 1986; 132(2):119-28. PubMed ID: 2431554
[TBL] [Abstract][Full Text] [Related]
8. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.
Wolanski KD; Whitaker D; Shilkin KB; Henderson DW
Cancer; 1998 Feb; 82(3):583-90. PubMed ID: 9452278
[TBL] [Abstract][Full Text] [Related]
9. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: the role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen.
Cibas ES; Corson JM; Pinkus GS
Hum Pathol; 1987 Jan; 18(1):67-74. PubMed ID: 2434407
[TBL] [Abstract][Full Text] [Related]
10. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions.
al-Saffar N; Hasleton PS
Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232
[TBL] [Abstract][Full Text] [Related]
11. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
12. The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma.
Marukawa M; Hiyama J; Shiota Y; Ono T; Sasaki N; Taniyama K; Mashiba H
Acta Med Okayama; 1998 Apr; 52(2):119-23. PubMed ID: 9588228
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemistry in the diagnosis of malignant mesothelioma.
Pfaltz M; Odermatt B; Christen B; Rüttner JR
Virchows Arch A Pathol Anat Histopathol; 1987; 411(4):387-93. PubMed ID: 2442887
[TBL] [Abstract][Full Text] [Related]
14. Benign pleural lesion and malignant mesothelioma.
Klima M; Gyorkey F
Virchows Arch A Pathol Anat Histol; 1977 Nov; 376(3):181-93. PubMed ID: 145715
[TBL] [Abstract][Full Text] [Related]
15. Immunohistological study of malignant diffuse mesotheliomas of the pleura.
Loosli H; Hurlimann J
Histopathology; 1984 Sep; 8(5):793-803. PubMed ID: 6083969
[TBL] [Abstract][Full Text] [Related]
16. [Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review].
Galateau-Salle F
Arch Anat Cytol Pathol; 1993; 41(5-6):212-22. PubMed ID: 8135582
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical differentiation of sarcomatoid mesotheliomas from other spindle cell neoplasms.
Cagle PT; Truong LD; Roggli VL; Greenberg SD
Am J Clin Pathol; 1989 Nov; 92(5):566-71. PubMed ID: 2479255
[TBL] [Abstract][Full Text] [Related]
18. Practical utility of insulin-like growth factor II mRNA-binding protein 3, glucose transporter 1, and epithelial membrane antigen for distinguishing malignant mesotheliomas from benign mesothelial proliferations.
Chang S; Oh MH; Ji SY; Han J; Kim TJ; Eom M; Kwon KY; Ha SY; Choi YD; Lee CH; Lee Y; Jung SH
Pathol Int; 2014 Dec; 64(12):607-12. PubMed ID: 25376377
[TBL] [Abstract][Full Text] [Related]
19. [A case of desmoplastic malignant mesothelioma with elevated serum CYFRA 21-1].
Nakamura H; Kitada O; Aragane K; Miyata S; Kodama T; Kuribayashi K; Nakagomi T; Takenaka N; Jin S; Nagasawa M; Sugita M
Nihon Kokyuki Gakkai Zasshi; 2002 Apr; 40(4):337-40. PubMed ID: 12096506
[TBL] [Abstract][Full Text] [Related]
20. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet-derived growth factor-receptor, P-glycoprotein and Bcl-2.
Attanoos RL; Griffin A; Gibbs AR
Histopathology; 2003 Sep; 43(3):231-8. PubMed ID: 12940775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]